CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--A drug being developed by DiaKine Therapeutics, Inc., which has shown in animals to prevent type 1 diabetes when given as a single therapy and to reverse diabetes when given in combination with a growth factor, is set to begin the first Company-sponsored clinical trial in humans. It is also the first clinical trial where Lisofylline (LSF) will be given to subjects under the skin (subcutaneously) using a convenient, ambulatory pump and the first time the drug will be tested to determine the effect it might have on certain inflammatory markers of type 1 diabetes.
